Follow
Tze Heng Tan
Tze Heng Tan
AstraZeneca
Verified email at tzeheng.com
Title
Cited by
Cited by
Year
Development and trends of biosurfactant analysis and purification using rhamnolipids as an example
M Heyd, A Kohnert, TH Tan, M Nusser, F Kirschhöfer, G Brenner-Weiss, ...
Analytical and bioanalytical chemistry 391, 1579-1590, 2008
2542008
Micropilot: automation of fluorescence microscopy–based imaging for systems biology
C Conrad, A Wünsche, TH Tan, J Bulkescher, F Sieckmann, F Verissimo, ...
Nature methods 8 (3), 246-249, 2011
1572011
Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis
KE Steele, TH Tan, R Korn, K Dacosta, C Brown, M Kuziora, ...
Journal for immunotherapy of cancer 6, 1-14, 2018
1022018
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
S Althammer, TH Tan, A Spitzmüller, L Rognoni, T Wiestler, T Herz, ...
Journal for immunotherapy of cancer 7, 1-12, 2019
1002019
Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial
T Cascone, G Kar, JD Spicer, R García-Campelo, W Weder, DB Daniel, ...
Cancer discovery 13 (11), 2394-2411, 2023
332023
Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
MA Silva, N Triltsch, S Leis, I Kanchev, TH Tan, B Van Peel, ...
The Journal of Pathology: Clinical Research 6 (2), 124-137, 2020
162020
31st annual meeting and associated programs of the society for immunotherapy of cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016
S Althammer, K Steele, M Rebelatto, TH Tan, T Wiestler, G Schmidt, ...
Journal for ImmunoTherapy of Cancer 4, 223-242, 2016
92016
929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC …
J Spicer, T Cascone, G Kar, Y Zheng, J Blando, TH Tan, M Cheng, ...
Annals of Oncology 33, S971, 2022
82022
Combinatorial CD8+ and PD-L1+ cell densities correlate with response and improved survival in non-small cell lung cancer (NSCLC) patients treated with durvalumab
S Althammer, K Steele, M Rebelatto, TH Tan, T Wiestler, G Schmidt, ...
J Immunother Cancer 4 (suppl 2), 91, 2016
42016
Quantitative continuous scoring of PD-L1 for superior patient selection for anti-PD-L1 treatment of locally advanced or unresectable NSCLC
JM Lesniak, I Bisha, S Christ, L Meinecke, T Padel, LS Monasor, ...
Cancer Research 84 (6_Supplement), 7617-7617, 2024
12024
Quantitative assessment of IHC using computational pathology allows superior patient selection for biomarker-informed patients
H Sade, A Kapil, P Wortmann, A Spitzmueller, N Triltsch, L Meinecke, ...
Cancer Research 82 (12_Supplement), 468-468, 2022
12022
Insights into the tumour immune microenvironment using tissue phenomics to drive cancer immunotherapy
M Groher, J Zimmermann, H Musa, A Ackermann, M Surace, ...
Annals of Oncology 30, v505, 2019
12019
The prognostic and predictive roles of a CD8/PD-L1 signature in cancer
S Althammer, K Steele, M Widmaier, C Brown, TH Tan, L Rognoni, ...
JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017
12017
Multiplex immunofluorescence profiling of the tumor microenvironment and CD73: Activity of neoadjuvant oleclumab in patients with non-small-cell lung cancer in NeoCOAST
I Bisha, TH Tan, M Weitkunat, A Andoni, I Dino, P Martin, M Saraiya, ...
Cancer Research 84 (6_Supplement), 2023-2023, 2024
2024
Development and implementation of image analysis-based Quantitative Continuous Score (QCS) for B7-H4 IHC to understand AZD8205 pharmacodynamics
P Wortmann, TH Tan, S Haneder, AE Storti, A Kapil, J Chesebrough, ...
Cancer Research 82 (12_Supplement), 452-452, 2022
2022
P1. 09-16 Tumor Proliferation Is Associated with the Tumor Immunological Status: A Study on NSCLC Using Multiplex Immunofluorescence
A Spitzmüller, TH Tan, M Surace, L Rognoni, D Chain, V Pawar, ...
Journal of Thoracic Oncology 14 (10), S502, 2019
2019
Dissemination score of CD8+ TILs by automated image analysis is a potential marker of immune activity in human cancers
S Bentink, A Spitzmueller, TH Tan, H Sade, S Wu, BW Higgs, KE Steele
Cancer Research 79 (13_Supplement), 2795-2795, 2019
2019
Abstract A069: Combination of immune status and tumor microvascularization provides strong prognostic markers for prostate cancer recurrence prediction
N Harder, M Athelogou, H Hessel, A Buchner, C Stief, T Kirchner, ...
Cancer Research 78 (16_Supplement), A069-A069, 2018
2018
Combination of immune status and tumor microvascularization provides strong prognostic markers for prostate cancer recurrence prediction.
N Harder, M Athelogou, H Hessel, A Buchner, C Stief, T Kirchner, ...
CANCER RESEARCH 78 (16), 62-62, 2018
2018
Characterizing cancers by prevalence on the PD-L1/CD8 axis
G Schmidt, K Steele, A Meier, T Herz, TH Tan, B Higgs, S Althammer, ...
JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–20